XNCR Xencor Inc

Price (delayed)

$27.12

Market cap

$1.61B

P/E Ratio

14.5

Dividend/share

N/A

EPS

$1.87

Enterprise value

$1.57B

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in ...

Highlights
The gross profit has soared by 163% YoY and by 19% from the previous quarter
XNCR's revenue has surged by 163% year-on-year and by 19% since the previous quarter
Xencor's debt has increased by 2.7% QoQ

Key stats

What are the main financial stats of XNCR
Market
Shares outstanding
59.54M
Market cap
$1.61B
Enterprise value
$1.57B
Valuations
Price to earnings (P/E)
14.5
Price to book (P/B)
2.11
Price to sales (P/S)
4.93
EV/EBIT
14.45
EV/EBITDA
13.46
EV/Sales
4.81
Earnings
Revenue
$326.64M
EBIT
$108.71M
EBITDA
$116.74M
Free cash flow
$5.51M
Per share
EPS
$1.87
Free cash flow per share
$0.09
Book value per share
$12.85
Revenue per share
$5.5
TBVPS
$14.16
Balance sheet
Total assets
$857.92M
Total liabilities
$94.9M
Debt
$34.89M
Equity
$763.02M
Working capital
$445.03M
Liquidity
Debt to equity
0.05
Current ratio
8.3
Quick ratio
7.84
Net debt/EBITDA
-0.37
Margins
EBITDA margin
35.7%
Gross margin
100%
Net margin
33.3%
Operating margin
26.3%
Efficiency
Return on assets
14.1%
Return on equity
15.7%
Return on invested capital
17.2%
Return on capital employed
13.6%
Return on sales
33.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

XNCR stock price

How has the Xencor stock price performed over time
Intraday
2.03%
1 week
17.81%
1 month
20.8%
1 year
-24.69%
YTD
-32.4%
QTD
1.65%

Financial performance

How have Xencor's revenue and profit performed over time
Revenue
$326.64M
Gross profit
$326.64M
Operating income
$85.91M
Net income
$108.71M
Gross margin
100%
Net margin
33.3%
Xencor's net margin has surged by 165% YoY and by 11% QoQ
The gross profit has soared by 163% YoY and by 19% from the previous quarter
XNCR's revenue has surged by 163% year-on-year and by 19% since the previous quarter
XNCR's operating margin has surged by 139% year-on-year and by 65% since the previous quarter

Growth

What is Xencor's growth rate over time

Valuation

What is Xencor stock price valuation
P/E
14.5
P/B
2.11
P/S
4.93
EV/EBIT
14.45
EV/EBITDA
13.46
EV/Sales
4.81
The EPS has increased by 32% QoQ
XNCR's P/B is 38% below its 5-year quarterly average of 3.4 and 27% below its last 4 quarters average of 2.9
XNCR's equity is up by 31% year-on-year and by 4% since the previous quarter
XNCR's revenue has surged by 163% year-on-year and by 19% since the previous quarter
XNCR's P/S is 78% below its 5-year quarterly average of 22.6 and 46% below its last 4 quarters average of 9.1

Efficiency

How efficient is Xencor business performance
The ROS has soared by 165% YoY and by 11% QoQ
The ROA has grown by 25% from the previous quarter
XNCR's ROE is up by 23% from the previous quarter
The ROIC has grown by 15% from the previous quarter

Dividends

What is XNCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XNCR.

Financial health

How did Xencor financials performed over time
The company's current ratio rose by 40% YoY and by 38% QoQ
XNCR's quick ratio is up by 39% year-on-year and by 39% since the previous quarter
Xencor's debt is 95% lower than its equity
The debt to equity has soared by 150% YoY
XNCR's equity is up by 31% year-on-year and by 4% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.